S-Gboxin retains excellent metabolic stability, enhanced plasma stability, and PK-properties suitable for in vivo studies. S-Gboxin (10 mg/kg/day; intraperitoneally) inhibits glioblastoma (GBM) growth in vivo[1].
| Animal Model: | Female nude mice (6 to 9 weeks)[1] |
| Dosage: | 10 mg/kg/day |
| Administration: | Administered intraperitoneally; daily; 3 or 14 days |
| Result: | Resulted in significant attenuation of growth and decreased cellular density compared to controls. |